LON:ERGO

Ergomed (ERGO) Share Price, News & Analysis

Ergomed logo

About Ergomed Stock (LON:ERGO)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
280,999 shs
Average Volume
346,578 shs
Market Capitalization
£701.00 million
P/E Ratio
4,641.38
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ERGO Stock News Headlines

Aktuelle Empfehlungen zur ERGOMED
Ergomedcro Unveils New Pune Office, Reinforcing Commitment to Global Growth
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Icon PLC IJF
Green Mining Innovation: Neuer Chief Financing Officer
Green Mining Innovation: New Chief Financing Officer
See More Headlines

ERGO Stock Analysis - Frequently Asked Questions

Ergomed plc (LON:ERGO) released its quarterly earnings results on Monday, September, 18th. The company reported GBX 1.20 earnings per share (EPS) for the quarter. The company had revenue of £22.91 million for the quarter. Ergomed had a net margin of 9.87% and a trailing twelve-month return on equity of 18.08%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Frontier Developments (FDEV), Future (FUTR), Axsome Therapeutics (AXSM), Walt Disney (DIS), Alpha FX Group (AFX), boohoo group (BOO) and Hollywood Bowl Group (BOWL).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:ERGO
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX 0.29
Trailing P/E Ratio
4,641.38
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£15 million
Net Margins
9.87%
Pretax Margin
N/A
Return on Equity
18.08%
Return on Assets
10.16%

Debt

Debt-to-Equity Ratio
3.32
Current Ratio
1.79
Quick Ratio
1.22

Sales & Book Value

Annual Sales
£152.09 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
54.67
Book Value
GBX 179 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
52,080,000
Free Float
N/A
Market Cap
£701.00 million
Optionable
Not Optionable
Beta
0.79
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (LON:ERGO) was last updated on 11/13/2023 by MarketBeat.com Staff.
From Our Partners